Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, PR China.
Cancer Lett. 2012 Mar 28;316(2):178-86. doi: 10.1016/j.canlet.2011.10.033. Epub 2011 Nov 2.
Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine protein kinase, plays a vital role in the tumorigenesis of many cancers, but its role in pancreatic cancer remains unknown. In this study, we showed that GSK-3β was aberrantly activated in pancreatic cancer. GSK-3β knockdown resulted in arrested proliferation and increased apoptosis in pancreatic cancer cell lines. Expression of Bcl-2 and vascular endothelial growth factor (VEGF) decreased significantly in a GSK-3β knockdown group. In a xenograft tumor model, GSK-3β knockdown inhibited tumor growth and angiogenesis. Our study showed that GSK-3β may become a promising therapeutic target for human pancreatic cancer.
糖原合酶激酶-3β（GSK-3β）是一种丝氨酸/苏氨酸蛋白激酶，在许多癌症的发生中起着至关重要的作用，但它在胰腺癌中的作用尚不清楚。在这项研究中，我们表明 GSK-3β在胰腺癌中异常激活。GSK-3β 敲低导致胰腺癌细胞系增殖停滞和凋亡增加。在 GSK-3β 敲低组中，Bcl-2 和血管内皮生长因子（VEGF）的表达显著降低。在异种移植肿瘤模型中，GSK-3β 敲低抑制肿瘤生长和血管生成。我们的研究表明，GSK-3β 可能成为人类胰腺癌有前途的治疗靶点。
